Soaring AstraZeneca (LSE: AZN) sales beat estimates in 2022’s first quarter, but the company’s full-year guidance remains unchanged amid an uncertain Covid-19-product sales outlook and Chinese market challenges.
Total revenue at the Anglo-Swedish drugmaker hit $11.39 billion, a 56% rise on the first quarter of 2021 and above analyst estimates of about $10.9 billion.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze